Treatment, tolerability and outcomes of enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: An analysis of the Austrian enfortumab registry.

D Niedersuess-Beke; R Pichler; J Krauter; F Luger; D Vais; R Taedcke; S Aufderklamm; F Stoiber; SF Shariat; S Schnabel; SP Gampenrieder; J Muehlmann; J Spiegelberg; T Bauernhofer; A Banner; S Weibrecht; C Wiesinger; J Miechowiecki; D Heintel; Katrin Mayrhofer

doi:10.1200/JCO.2025.43.5_suppl.736

Treatment, tolerability and outcomes of enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: An analysis of the Austrian enfortumab registry.

D Niedersuess-Beke
, R Pichler
, J Krauter
, F Luger
, D Vais
, R Taedcke
, S Aufderklamm
, F Stoiber
, SF Shariat
, S Schnabel
, SP Gampenrieder
, J Muehlmann
, J Spiegelberg
, T Bauernhofer
, A Banner
, S Weibrecht
, C Wiesinger
, J Miechowiecki
, D Heintel
, Katrin Mayrhofer

Department of Urology

Research output: Contribution to journal › Conference abstract

Original language	English
Article number	736
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	43
Issue number	5_SUPPL
DOIs	https://doi.org/10.1200/JCO.2025.43.5_suppl.736
Publication status	Published - 10 Feb 2025
Event	American Society of Clinical Oncology and Society of Urologic Oncology 2025 Genitourinary Cancers Symposium - San Francisco, United States Duration: 13 Feb 2025 → 15 Feb 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Branches of science

302 Clinical Medicine

DOI

10.1200/JCO.2025.43.5_suppl.736

Links

Web of Science

Treatment, tolerability and outcomes of enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: An analysis of the Austrian enfortumab registry.
Niedersuess-Beke, D. (Author), Pichler, R. (Author), Krauter, J. (Author), Luger, F. (Author), Vais, D. (Author), Taedcke, R. (Author), Aufderklamm, S. (Author), Stoiber, F. (Author), Shariat, S. (Author), Schnabel, S. (Author), Gampenrieder, S. (Author), Muehlmann, J. (Author), Spiegelberg, J. (Author), Bauernhofer, T. (Author), Banner, A. (Author), Weibrecht, S. (Author), Wiesinger, C. (Author), Miechowiecki, J. (Author), Heintel, D. (Author) & Mayrhofer, K. (Author)
2025
Activity: Talk, presentation or poster › Poster

Cite this

Niedersuess-Beke, D., Pichler, R., Krauter, J., Luger, F., Vais, D., Taedcke, R., Aufderklamm, S., Stoiber, F., Shariat, SF., Schnabel, S., Gampenrieder, SP., Muehlmann, J., Spiegelberg, J., Bauernhofer, T., Banner, A., Weibrecht, S., Wiesinger, C., Miechowiecki, J., Heintel, D., & Mayrhofer, K. (2025). Treatment, tolerability and outcomes of enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: An analysis of the Austrian enfortumab registry. Journal of Clinical Oncology, 43(5_SUPPL), Article 736. https://doi.org/10.1200/JCO.2025.43.5_suppl.736

@article{7c8234ce0825441fbf87fa45d65f428d,

title = "Treatment, tolerability and outcomes of enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: An analysis of the Austrian enfortumab registry.",

author = "D Niedersuess-Beke and R Pichler and J Krauter and F Luger and D Vais and R Taedcke and S Aufderklamm and F Stoiber and SF Shariat and S Schnabel and SP Gampenrieder and J Muehlmann and J Spiegelberg and T Bauernhofer and A Banner and S Weibrecht and C Wiesinger and J Miechowiecki and D Heintel and Katrin Mayrhofer",

year = "2025",

month = feb,

day = "10",

doi = "10.1200/JCO.2025.43.5\_suppl.736",

language = "English",

volume = "43",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "5\_SUPPL",

note = "American Society of Clinical Oncology and Society of Urologic Oncology 2025 Genitourinary Cancers Symposium, ASCO GU 2025 ; Conference date: 13-02-2025 Through 15-02-2025",

}

Niedersuess-Beke, D, Pichler, R, Krauter, J, Luger, F, Vais, D, Taedcke, R, Aufderklamm, S, Stoiber, F, Shariat, SF, Schnabel, S, Gampenrieder, SP, Muehlmann, J, Spiegelberg, J, Bauernhofer, T, Banner, A, Weibrecht, S, Wiesinger, C, Miechowiecki, J, Heintel, D & Mayrhofer, K 2025, 'Treatment, tolerability and outcomes of enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: An analysis of the Austrian enfortumab registry.', Journal of Clinical Oncology, vol. 43, no. 5_SUPPL, 736. https://doi.org/10.1200/JCO.2025.43.5_suppl.736

TY - JOUR

T1 - Treatment, tolerability and outcomes of enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: An analysis of the Austrian enfortumab registry.

AU - Niedersuess-Beke, D

AU - Pichler, R

AU - Krauter, J

AU - Luger, F

AU - Vais, D

AU - Taedcke, R

AU - Aufderklamm, S

AU - Stoiber, F

AU - Shariat, SF

AU - Schnabel, S

AU - Gampenrieder, SP

AU - Muehlmann, J

AU - Spiegelberg, J

AU - Bauernhofer, T

AU - Banner, A

AU - Weibrecht, S

AU - Wiesinger, C

AU - Miechowiecki, J

AU - Heintel, D

AU - Mayrhofer, Katrin

PY - 2025/2/10

Y1 - 2025/2/10

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:001454740800032

U2 - 10.1200/JCO.2025.43.5_suppl.736

DO - 10.1200/JCO.2025.43.5_suppl.736

M3 - Conference abstract

SN - 0732-183X

VL - 43

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 5_SUPPL

M1 - 736

T2 - American Society of Clinical Oncology and Society of Urologic Oncology 2025 Genitourinary Cancers Symposium

Y2 - 13 February 2025 through 15 February 2025

ER -

Treatment, tolerability and outcomes of enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: An analysis of the Austrian enfortumab registry.

UN SDGs

Branches of science

DOI

Links

Activities

Treatment, tolerability and outcomes of enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: An analysis of the Austrian enfortumab registry.

Cite this